^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners

    TEST:
    TriNetra™

    Company:
    Datar Cancer Genetics
    Type:
    CE Marked
    Related tests:
    Details
    Evidence

    News

    1year
    Early Detection of Breast Cancer (clinicaltrials.gov)
    P=N/A; N=700; Recruiting; Sponsor:Datar Cancer Genetics Inc
    New trial • Tumor cell
    |
    TriNetra™
    2years
    Clinical validation of “TriNetra™-Breast” test for breast cancer screening in a prospective, observational, case-cohort study (SABCS 2022)
    The results of TriNetra™-Breast will be compared with the results of mammography and/or histopathology for performance estimation of the test. Study participants will be followed for clinical outcomes for maximum duration of 2 years.
    Observational data • Clinical
    |
    TriNetra™
    3years
    FDA Grants Breakthrough Designation for Early-Stage Breast Cancer Detection Blood Test Developed by Datar Cancer Genetics (PRNewswire)
    "Datar Cancer Genetics...announced that the US Food and Drug Administration (FDA) has granted 'Breakthrough Device Designation' for its 'TriNetra™' blood test to detect early-stage Breast Cancer...TriNetra™ uses a proprietary technology developed by the Company to detect Circulating Tumor Cells (CTCs) specific to Breast Cancer. Studies have shown that TriNetra™ can detect even Stage 0 (DCIS) and Stage 1 cancers with high accuracy. The test requires only 5 ml blood and is indicated for asymptomatic women above the age of 40 years with a physician's prescription."
    Breakthrough therapy designation • FDA event
    |
    TriNetra™